Search

Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy‐free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph‐like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front‐line treatment of patients with Ph + ALL. [ABSTRACT FROM AUTHOR]

This article discusses a rare case of plasma cell myeloma, a type of cancer, occurring after a bone marrow transplant. The patient, a 48-year-old male, developed the condition after receiving a stem cell transplant for acute myeloid leukemia. The cancer was found to be positive for the Epstein-Barr virus (EBV), and the patient was successfully treated with a combination of bortezomib, thalidomide, and dexamethasone. The treatment resulted in a very good partial response, and the patient has remained disease-free for over three years. The article highlights the rarity of this condition and the need for further research and treatment protocols. [Extracted from the article]